Abcam, ab240031, Anti-Monoamine Oxidase A/MAO-A antibody [EPR7101] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal Monoamine Oxidase A/MAO-A antibody. Carrier free. Suitable for IHC-P, WB, ICC/IF, Flow Cyt (Intra) and reacts with Rat, Mouse, Human samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR7101,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse, Rat, Human,
Applications:IHC-P, WB, ICC/IF, Flow Cyt (Intra)See reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab240031 is the carrier-free version of
ab126751
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Monoamine Oxidase A (MAO-A) also known as MAO protein is an enzyme that degrades neurotransmitters through oxidative deamination. It possesses a mass of approximately 59 kDa. This enzyme is found localized in the outer mitochondrial membrane of cells specifically in high concentrations in the brain liver and intestine. MAO-A plays an important role in the breakdown of monoamine neurotransmitters such as serotonin norepinephrine and dopamine which are critical for normal brain function.
Biological function summary
MAO-A acts to maintain proper neurotransmitter levels by catalyzing the oxidative deamination of monoamines. It is not part of a larger protein complex but functions independently to influence monoamine balance. Through its enzymatic activity MAO-A regulates several physiological processes including mood and emotional responses by controlling neurotransmitter availability and preventing their accumulation to neurotoxic levels.
Pathways
MAO-A operates within the catabolic pathways that reduce the bioavailability of monoamines. It pairs with proteins like Catechol-O-methyltransferase (COMT) in the metabolic degradation of catecholamines. This pathway is integral to managing the equilibrium of mood-related neurotransmitters and involves complex interactions with other enzymatic systems including MAO-B which targets different substrates.
MAO-A is closely associated with psychiatric conditions such as depression and anxiety. Altered MAO-A activity can dysregulate monoamine levels contributing to these disorders. Additionally research links MAO-A dysregulation to neurodegenerative diseases like Parkinson's disease where imbalances in monoamine levels play a role. This enzyme interacts with proteins involved in early stages of these diseases highlighting its potential as a target for therapeutic interventions using MAO inhibitors.